Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy ...

Leerink Partners started coverage on Mind Medicine (MindMed) in a report on Monday, October 14th. They issued an “outperform” rating and a $20.00 price objective for the company. Leerink ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever In other Mind Medicine (MindMed) news, insider Dan Karlin sold 6,871 shares of the company’s stock ...

Mind Medicine (MNMD) announced that it will be ... and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December. Published first on TheFly ...

NEW YORK, December 11, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...

Mind Medicine (MNMD) has released an update. Mind Medicine, a biopharmaceutical company focused on brain health disorders, has announced its participation in major upcoming investor conferences ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is making waves in the biopharmaceutical industry with its innovative approach to mental health treatment. The company's focus on ...

Oppenheimer analyst Francois Brisebois maintained a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $7.40.

Mind Medicine (MNMD) announced the appointment of Gregg Pratt as chief regulatory and quality assurance officer. Pratt will serve as a member of the executive committee and oversee the company’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...